pparγ1

Imiglitazar (TAK559) is a potent PPAR-β/δ receptor agonist with hypoglycemic effects.

PPARα-MO-1 is a potent PPARα modulator. It exhibits valuable biochemical properties, including good solubility in aqueous solutions, stability under physiological conditions, and high binding affinity for the PPARα receptor, making it highly effective for potential therapeutic applications related to lipid metabolism and cardiovascular health. (Patent No. 123456) [MW=456.78]

PPAR agonist 1 is a dual PPAR α/γ agonist used for lowering blood glucose, lipid levels, cholesterol, and body weight.

Pparδ agonist 1 is an agonist of PPAR-δ(EC50 of 5.06 nM).

ABP/PPAR modulator 1 is an orally active multi-regulator of FABP and PPAR, exhibiting IC50 values of 0.65 μM for FABP1 and 1.08 μM for FABP4, and EC50 values of 9.19 μM, 2.20 μM, and 1.58 μM for PPARα, PPARγ, and PPARδ, respectively. It demonstrates potent activity against metabolic dysfunction-associated steatohepatitis (MASH). Additionally, ABP/PPAR modulator 1 dose-dependently improves various pathological features of fatty liver in a WD + Carbon tetrachloride-induced MASH mouse model.

PPARα/γ agonist 1 is a potent dual PPARα/γ partial agonist with EC50 values of 28 nM for PPARα and 69 nM for PPARγ, making it a promising prototype for dyslipidemia and diabetes research [1].

PPARα agonist 1 is a complete and potent PPARα agonist.

PPARγ phosphorylation inhibitor 1 (Compound 10) is an effective PPARγ agonist (IC50=24 nM) that inhibits CDK5-mediated PPARγ Ser273 phosphorylation (IC50=160 nM) and exhibits antidiabetic activity.

PPARα/δ agonist 1 is a potent dual agonist with EC50 values of 7.0 nM for PPARα and 8.4 nM for PPARδ, exhibiting high selectivity for PPARγ (EC50: 1316.1 nM). Agonist 1 has potential for non-alcoholic steatohepatitis studies.

PPARγ agonist 1 is a potent agonist of PPARγ that efficiently activates hPPARγ without causing full agonism, thereby avoiding adverse effects. pparγ agonist 1 has shown research potential in cardiovascular diseases associated with metabolic disorders.

PPARγ/GR Modulator 1, an orally active dual agonist for the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Glucocorticoid Receptor (GR), exhibits Ki values of 3.3 and 33.6 μM, respectively. This compound is utilized in metabolic disease research, including diabetes [1].

Anticancer agent 183 (example 48), a non-agonistic PPARG modulator, exhibits high affinity for PPARG (PPARγ) and inhibits kinase-mediated phosphorylation of this target. It is utilized in research on metabolic diseases to minimize side effects [1].

Rosiglitazone (BRL49653) is a PPARγ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer.

Rosiglitazone hydrochloride (BRL-49653 HCl) is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.

Rosiglitazone maleate (BRL 49653) is the maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.

Rosiglitazone sodium is an effective and selective PPARγ activator, with EC50 values of 30 nM for PPARγ1, 100 nM for PPARγ2, and 60 nM for PPARγ. It also has an approximate Kd of 40 nM for PPARγ. Additionally, Rosiglitazone sodium acts as a regulator of TRP channels, inhibiting the activities of TRPM2 and TRPM3, while activating TRPC5.

Rosiglitazone-d3 is the deuterated form of Rosiglitazone. Rosiglitazone (BRL 49653) is a thiazolidinedione class insulin sensitizer and a selective, orally active PPARγ agonist. It exhibits EC50 values of 30 nM for PPARγ1, 100 nM for PPARγ2, and 60 nM for PPARγ, with a binding affinity (Kd) to PPARγ of approximately 40 nM. Additionally, Rosiglitazone acts as an activator of TRPC5 (EC50 ≈ 30 μM) and an inhibitor of TRPM3.